100 related articles for article (PubMed ID: 2306706)
21. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
Lakaschus G; Löffler M
Biochem Pharmacol; 1992 Mar; 43(5):1025-30. PubMed ID: 1313236
[TBL] [Abstract][Full Text] [Related]
22. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
[TBL] [Abstract][Full Text] [Related]
23. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Noe DA; Rowinsky EK; Shen HS; Clarke BV; Grochow LB; McGuire WB; Hantel A; Adams DB; Abeloff MD; Ettinger DS
Cancer Res; 1990 Aug; 50(15):4595-9. PubMed ID: 2369734
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
Guo B; Cao S; Tóth K; Azrak RG; Rustum YM
Clin Cancer Res; 2000 Feb; 6(2):718-24. PubMed ID: 10690558
[TBL] [Abstract][Full Text] [Related]
26. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.
Boven E; Winograd B; Berger DP; Dumont MP; Braakhuis BJ; Fodstad O; Langdon S; Fiebig HH
Cancer Res; 1992 Nov; 52(21):5940-7. PubMed ID: 1394220
[TBL] [Abstract][Full Text] [Related]
27. Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.
Pizzorno G; Wiegand RA; Lentz SK; Handschumacher RE
Cancer Res; 1992 Apr; 52(7):1660-5. PubMed ID: 1551097
[TBL] [Abstract][Full Text] [Related]
28. The effect of high dose vitamin A on the morphology and proliferative activity of xenograft lung and head and neck cancer.
Mourad WA; Bruner JM; Vallieres E; McName C; Alabdulwahed S; Scott K; Oldring DJ
In Vivo; 1996; 10(3):329-33. PubMed ID: 8797035
[TBL] [Abstract][Full Text] [Related]
29. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
[TBL] [Abstract][Full Text] [Related]
30. Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts.
Görögh T; Quabius ES; Heidebrecht H; Nagy A; Muffels T; Haag J; Ambrosch P; Hoffmann M
Int J Cancer; 2016 May; 138(10):2529-38. PubMed ID: 26756583
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
33. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
[TBL] [Abstract][Full Text] [Related]
34. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors.
Zacheis D; Dhar A; Lu S; Madler MM; Klucik J; Brown CW; Liu S; Clement F; Subramanian S; Weerasekare GM; Berlin KD; Gold MA; Houck JR; Fountain KR; Benbrook DM
J Med Chem; 1999 Oct; 42(21):4434-45. PubMed ID: 10543887
[TBL] [Abstract][Full Text] [Related]
35. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
[TBL] [Abstract][Full Text] [Related]
36. Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis.
Kobayashi K; Nakashima A; Nagata H; Nakajima H; Yamaguchi K; Sato S; Miki I
Inflamm Res; 2001 Jan; 50(1):24-31. PubMed ID: 11235018
[TBL] [Abstract][Full Text] [Related]
37. The relationship between dihydroorotic acid dehydrogenase and in vitro and in vivo cytostatic effects of brequinar sodium (DUP-785; NSC 368390).
Peters GJ; Laurensse E; de Kant E; Nadal JC; Pinedo HM
Adv Exp Med Biol; 1989; 253B():375-82. PubMed ID: 2558540
[No Abstract] [Full Text] [Related]
38. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
39. In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts.
Skipper JB; McNally LR; Rosenthal EL; Wang W; Buchsbaum DJ
ORL J Otorhinolaryngol Relat Spec; 2009; 71(1):1-5. PubMed ID: 18931526
[TBL] [Abstract][Full Text] [Related]
40. Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor.
Singh T; Gupta NA; Xu S; Prasad R; Velu SE; Katiyar SK
Oncotarget; 2015 Aug; 6(25):21268-82. PubMed ID: 26020804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
